Kim Allman

[Kim Allman @KimAllman4]

@shilpaonc @BladderCancerUS @CleClinicMD @ClevelandClinic @PGrivasMDPhD @DrOmarMian @GeneCollector @MosheOrnsteinMD @ChrisWeeMD @AmandaNizamMD @caseccc @CleClinicUro @LauraBukavinaMD Ha! That’s great!

[Katy Beckermann @katy_beckermann]

📸 Learning from @kidneycancerdoc at #worldgu25 on imaging for kidney masses. Novel modalities on the horizon, including CAIX-PSMA, with the FDA set to weigh in next week 🔬💡 Exciting times for #RCC care! #kidneycancer #GUonc

[Kim Allman @KimAllman4]

@montypal @JasnoorMalhotra @UCRiverside @DrChoueiri @VivekSubbiah @timir_paul @neerajaiims @PGrivasMDPhD @rachnatshroff @ReginaBarCar @NazliDizman @DrRaviSalgia @cityofhope Awesome story!

[Christine Collins @CCollinsKCC]

Juravinski/Walker Cancer Centres Forum 2025 @CanUrolAssoc Excellent presentation by Kimberly Allman of Telix on Novel Theranostics - a diagnostic agent. Not in Canada yet but hopefully coming soon!
#kidneycancer @KidneyCancer_Ca @CancerduRein

[Telix Pharmaceuticals @TelixPharma]

The U.S. FDA has accepted Telix’sBiologics License Application (BLA) for its investigational kidney cancer imaging agent TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), granting a Priority Review with a PDUFA date of August 27, 2025.

This acceptance brings this breakthrough product one step closer to patients and paves the way for a U.S. commercial launch in 2025.

If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common and one of the most aggressive sub-types of kidney cancer.

Read more on our website here: https://t.co/G4CvVIqsjk

[Kim Allman @KimAllman4]

@katy_beckermann Congratulations, Katy! They are so lucky to have you.

[Telix Pharmaceuticals @TelixPharma]

Telix today announces that it has submitted its Biologics License Application (BLA) to the U.S. FDA for TLX250-CDx (Zircaix®, 89Zr-girentuximab) kidney cancer imaging.

TLX250-CDx is an investigational PET drug product for the non-invasive diagnosis and characterisation of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.

If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix’s successful urology imaging franchise.

Read more on our website here: https://t.co/ySFpny0WDT

TLX250-CDx has not received a marketing authorisation in any jurisdiction.

[Telix Pharmaceuticals @TelixPharma]

Today marked an important milestone for Telix as we commenced trading on the @Nasdaq under the ticker “TLX”.

We reaffirm our founding commitment to building a world-class global business, that delivers on the promise of precision medicine through targeted radiation, helping people with cancer and rare diseases live longer, better quality lives.

Listing on Nasdaq is key towards achieving these goals, and an appropriate step given our growth trajectory, leadership position in radiopharmaceuticals and expanding footprint in North America.

We would like to thank the many who have helped us reach this point.

Read more on our website here: https://t.co/6yfharauDI

This does not constitute an offer to sell or the solicitation of an offer to buy any securities of Telix.

[Kim Allman @KimAllman4]

@kaydaustin Congratulations, Katie!

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just in @MedCellPress 👉Excellent viewpoint by our trainee, Chadi @chadihc98 👉The novel Zirconium-girentuximab PET-CT is set to change the diagnostic paradigm of ccRCC #kidneycancer (akin to PSMA-PET in #prostatecancer)👇
https://t.co/Ar2erC3HhG @ggebraelmd @urotoday @OncoAlert

[Kim Allman @KimAllman4]

@MosheOrnsteinMD @shilpaonc @CleClinicMD @PBarataMD @caseccc @Browns Very cool!

[KidneyCAN @kidneycan]

Out today in @TIME — a review of recent advances in #KidneyCancer treatment highlighting the incredible work of @DrChoueiri @DanaFarber_GU
@brian_rini @VUMCHemOnc
@UroWCH @nyulmc
@Katie_Spina @ColumbiaRadOnc
@schadegr @fredhutch
and many others!

It takes a village to #AccelerateCures for #RCC, and our village is strong 💪

🔗 https://t.co/KGnWjzi8MR

[Kim Allman @KimAllman4]

@ZakhariaYousef @IMG_Oncologists Congratulations, Yousef!

[Kim Allman @KimAllman4]

@ThirdEyeBlind @Mandelicatessen!!

[Kim Allman @KimAllman4]

@shilpaonc @jamecancerdoc Congratulations, Shilpa!! So well deserved!!

[Kim Allman @KimAllman4]

@koshkin85 @UCSF @UCSFMedicine @UCSFCancer @PGrivasMDPhD @GUONCGarciaJA @brian_rini @neerajaiims @montypal @charlesryanmd @SimaPorten @thomashopemd @AlvaAjjai @drkomanduri @PBarataMD @arnabguonc @Tanjin097 @AmandaNizamMD @arkhaki @DrOmarMian @OAlhalabiMD @DocMattCampbell @DrTFriedlander @shilpaonc Congratulations, Vadim!!

[Kim Allman @KimAllman4]

@shilpaonc Enjoy, Shilpa! 😎

[Kim Allman @KimAllman4]

@shilpaonc @CleClinicMD @Uromigos @tompowles1 @MichvdHeijden @MosheOrnsteinMD @AmandaNizamMD @ChrisWeeMD @n8pennell @jamecancerdoc @caseccc @BladderCancerUS Amazing story! Wonderful news!

[Kim Allman @KimAllman4]

@KunalDesaiMD @abbvie Congratulations, Kunal!

[Kim Allman @KimAllman4]

@MosheOrnsteinMD Go MO!